Rotem, the US subsidiary of Tem International, has received the US Food and Drug Administration (FDA) approval for its hemostasis delta analyzer.

The Rotem testing is performed on whole blood samples and provides information on the complex biological process of coagulation.

The results are obtained to the OR on a variety of coagulation parameters which aids the surgical team to decide whether platelets, plasma, red blood cells or other blood components are in proper balance or need to be augmented by transfusion.

Rotem president Ken West said surgeons can get more complete hemostasis information and use this information to help decide whether there is a need for a transfusion and which blood products to transfuse.

"With the FDA clearance, we can offer the full Rotem technology to hospitals, blood banks and research centers," West said.